Clinical trial
Topotecan in Treating Patients With Myelodysplastic Syndrome
NCT00003675 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003675 |
|---|---|
| Title | Topotecan in Treating Patients With Myelodysplastic Syndrome |
| Official title | A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Enrollment | 100 |
| Start date | Mar 1, 1999 |
| Primary completion | Jan 1, 2002 |
| Completion | Apr 1, 2009 |
| First posted | Jul 22, 2004 |
| Last update posted | Jul 20, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: